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AbstrAct Eradication of HCV in patients with advanced liver fibrosis or cirrhosis reduces, 
but does not altogether abolish, the risk of development of hepatocellular carcinoma. The 
reasons underlying this residual risk remain elusive. Even if HCV clearance eliminates its direct 
and indirect carcinogenic effects, the persistence of cirrhosis and the possible coexistence of 
metabolic factors (diabetes, obesity and insulin resistance) and of alcohol abuse can promote 
the development of hepatocellular carcinoma acting as autonomous, nonviral carcinogenic 
factors. Lessons learned in the IFN era may still assist in predicting the forthcoming scenario, 
when IFN-free regimens will obtain high rates of viral clearance even at the most advanced 
stages of liver disease.
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Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance, being the 
second cause of cancer-related death worldwide [1]. The majority of HCCs occur in the context of 
chronic infection with HBV and HCV, and the cancer risk is directly related to the histological 
and clinical stage of the underlying liver disease [2]. In particular, HCV infection stands today as 
the leading risk factor for HCC in many industrialized countries [3], occurring at a rate between 
3 and 8%, according to the geographic area, in patients with HCV-related cirrhosis [4]. On these 
assumptions, prevention of population exposure to HCV can be regarded as the most effective tool 
to reduce liver-related mortality from HCC due to chronic HCV infection. In the HCV scenario, 
where an effective vaccine is not currently available, antiviral treatments have stood as the real 
backbone of prophylaxis strategy in the prevention of HCC, of course together with all procedures 
implemented to prevent HCV transmission [5].
However, the evidence that patients with chronic hepatitis C (CHC) are completely protected 
against occurrence of HCC by successful IFN-based treatments is controversial, mainly due to 
methodological limitations of available literature. All in all, HCC risk seems to be sharply attenu-
ated, although not completely eliminated – especially in patients with advanced fibrosis – following 
eradication of HCV infection, and the causes for this residual HCC risk in patients who achieved a 
sustained virological response (SVR) remain receding. Moreover, the intrinsic limitations of the use 
of IFN to patients with less advanced liver disease have curtailed the potential benefit, due to the fact 
that HCC in HCV cirrhosis becomes more prevalent at the more advanced stages of liver disease.
In this review, we discuss the available clinical evidence of the role of antiviral treatment against 
chronic HCV infection for the prevention of HCC, and the residual risk existing in patients suc-
cessfully treated. In addition, we focus on the molecular mechanisms that might explain the patho-
physiological rationale of the reduction, but not elimination, of HCC risk after HCV eradication. 
The lesson from the IFN era may be extremely useful to predict the near-future scenario, when 
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the IFN-free regimens will determine extremely 
high rate of SVR and will also be administered 
to patients with advanced or decompensated cir-
rhosis, thus reducing dramatically liver-related 
events – including HCC – and mortality due to 
HCV infection.
The role of antiviral treatment for the 
prevention of HCv-related HCC
As previously mentioned, the evidence that 
patients with CHC are effectively protected 
against HCC risk by IFN-based regimens is 
rather controversial, due to several methodologi-
cal concerns in the literature on this topic [6]. 
First, most of the available evidence examin-
ing the relationship between SVR and HCC is 
observational and retrospective, so that treat-
ment outcomes could not properly be adjusted 
for important risk factors for HCC such as age, 
HCV genotype, coinfections with HBV or HIV, 
fibrosis stage, other well-known potential carci-
nogenic factors (for example diabetes, obesity 
and alcohol abuse) and presence of advanced 
liver disease and comorbidities – the latter two 
causes of ineligibility to IFN-based treatments. 
Indeed, it should be noted that the exclusion 
to IFN-based treatments of patients with severe 
comorbidities and advanced/decompensated 
chronic liver disease, in other words, the closest 
to develop HCC, might have caused an over-
estimation of risk reduction of HCC and all-
cause mortality in the cohorts of HCV patients 
who achieved an SVR [7]. In addition, long-term 
outcomes of treatments against chronic HCV 
infection are difficult to assess because, on the 
one hand, the diagnosis of HCV infection often 
occurs after symptoms appearance, in other 
words, at a late stage of disease, and, on the other 
hand, natural history studies of cohorts success-
fully treated for HCV typically have inadequate 
length of follow-up in relation to the outcomes 
of interest, which may occur after several dec-
ades. Nonetheless, the evidence seems sufficient 
to state that HCV-related HCC is more likely to 
be prevented in young patients with mild fibrosis 
achieving an SVR, rather than in elderly patients 
with cirrhosis [8].
One of the first studies regarding the poten-
tial role of antiviral therapy in preventing HCV-
related HCC in cirrhotic patients derived from 
a small Japanese trial published in 1995 [9]: 
HCC occurred only in two out of 90 patients 
(4%) with HCV-related cirrhosis treated with 
IFN-α, a much smaller proportion if compared 
with untreated controls (38%), resulting in a 
risk ratio of IFN-α treatment versus no treat-
ment of 0.067. Along this line, the Inhibition 
of hepatocarcinogenesis by interferon therapy 
(IHIT) – a Japanese national surveillance pro-
gram conducted during the 1990s – provided 
further evidence for a significant reduction 
of HCC risk in patients with any histologi-
cal stage of hepatitis C capable to achieve an 
SVR [10]. Similarly, several subsequent observa-
tional studies conducted both in Western and 
Asiatic cohorts confirmed this chemopreventive 
effect of IFN-based treatments on HCC occur-
rence [11–31] (Table 1). However, it was initially 
debated if this clinical benefit could be gained 
with antiviral treatment only, independent from 
the achievement of an SVR, in other words, 
also in nonresponder patients. Indeed, IFN has 
potential antitumor effects, being likely associ-
ated to its immunomodulatory action as well as 
to the in vitro ability of IFN to influence cellu-
lar differentiation and proliferation of neoplastic 
cells [32]. This issue was subsequently clarified by 
several large cohort studies, which highlighted 
how the risk reduction of HCC development 
was substantial in SVR patients only compared 
with non-SVR ones. A multicenter retrospective 
study conducted on 920 Italian patients with 
histologically proven cirrhosis, who received 
IFN monotherapy and were followed up for a 
median period of 96 months after the end of 
treatment, showed not only lower rates of liver-
related complications (0 vs 1.88 per 100 per-
son-years), but also of HCC occurrence (0.66 
vs 2.10 per 100 person-years) in SVR patients 
compared with non-SVR [20]. Along the same 
line, Cardoso et al. performed a cohort study 
on 307 French patients with bridging fibrosis or 
cirrhosis followed up for a median of 3.5 years 
after the end of antiviral treatment, showing 
that incidence rates of HCC were lower in 
SVR patients compared with non-SVR (1.24 vs 
5.85 per 100 person-years), and that the lack 
of SVR was a strong independent predictor of 
HCC (hazard ratio [HR]: 3.06) [26]. Similar 
conclusions were argued by Veldt et al. with 
their retrospective cohort study performed on 
North American patients with advanced fibrosis, 
where an SVR was associated to a reduced risk 
of any liver-related events (adjusted HR: 0.21), 
and with a lower occurrence of HCC, although 
this reduction was not statistically significant, 
probably due to the limited follow-up of the 
study (median 2.1 years) [27]. Finally, our group 
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recently performed a prospective cohort study 
aiming to evaluate the long-term clinical ben-
efit of HCV eradication in patients with com-
pensated cirrhosis with or without esophageal 
varices [33]. The outcomes of 440 patients con-
secutively treated with Peg-IFN and Ribavirin 
were recorded and analyzed. After a median 
follow-up of 87 months, the incidence of HCC 
in patients without esophageal varices at baseline 
was 0.77 per 100 person-years for SVR patients 
versus 3.45 per 100 person-years for non-SVR 
patients, while in patients with esophageal varices 
at baseline the incidence of HCC was 0.95 per 
100 person-years for SVR patients and 4.77 per 
100 person-years for non-SVR ones. Thus, SVR 
was associated with a significant reduction in the 
incidence of HCC in both groups, even if the 
global incidence of HCC was not statistically 
different between the two subgroups, in other 
words, not affected by the degree of portal hyper-
tension. Furthermore, analysis of data has identi-
fied the variables independently associated with 
a higher risk of HCC development, and among 
them (age, male gender, gGT value and SVR) 
the presence of varices and the Child-Pugh score 
did not appear. Of note, different results were 
observed about the role of SVR in preventing 
the ‘de novo’ occurrence of esophageal varices. 
Indeed, SVR was the unique variable indepen-
dently associated with a reduction of the risk of 
esophageal varices development in patients with-
out varices at baseline. Conversely, SVR patients 
with small varices at baseline may experience a 
progression to large varices even if an SVR was 
achieved. Regarding liver decompensation and 
mortality, we have observed a significant associa-
tion between virological response and the occur-
rence of liver events in both patients with and 
without EV, although the formers maintained 
a risk to develop liver decompensation and to 
die in consequence of liver events even after 
SVR achievement. Further evidences were pro-
vided from three randomized controlled trials 
– HALT-C [34], COPILOT [35] and EPIC-3 [36] 
– that investigated the effectiveness of a long-
term maintenance therapy with pegylated-IFN 
in nonresponder HCV patients with advanced 
fibrosis or cirrhosis. The outcomes assessed were 
death, hepatic decompensation, HCC develop-
ment and an increase in hepatic fibrosis for non-
cirrhotic patients: overall, a poor benefit of main-
tenance therapy on clinical outcomes – including 
HCC – was observed, despite the reduction of 
viral load and the improvement of inflammatory S
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markers. Of note, data from HALT-C trial with 
an extended follow-up (up to 8 years) showed 
that the cumulative rate of HCC was lower in 
treated cirrhotic patients compared with con-
trols, thus demonstrating a modest benefit of 
long-term pegylated-IFN treatment in decreas-
ing the incidence of HCC in patients with cir-
rhosis [37]. Furthermore, several meta-analyses 
have resumed and emphasized the relationship 
between achievement of SVR and subsequent 
risk reduction of HCC [38–41]; the most recent 
one by Morgan et al. [42], including 30 obser-
vational studies on this topic, led to quantify 
in almost 80% the reduction of the HCC risk 
across all clinical stages of CHC occurring in 
SVR patients compared with non-SVR.
All in all, these studies universally concluded 
that SVR is associated with a robust reduction of 
HCC occurrence, also among persons who have 
progressed to advanced liver disease. However, as 
previously stated, the strength of this association 
remains undefined, mainly due to the methodo-
logical issues affecting original, uncontrolled, 
studies producing incorrect effect estimates [6].
The residual risk of HCC among SvR 
patients
It should be pointed out that all the aforemen-
tioned reports highlighted only a significant 
reduction, but never a complete elimination, 
of the risk of HCC development after HCV 
eradication. Indeed, common to all these stud-
ies was the persistence of HCC occurrence in a 
minority of patients despite their achievement 
of an SVR. Several studies focused specifically 
on this issue (Table 2), showing that HCC devel-
ops in 2.5–4% of SVR patients [43–45]. In this 
line, a large multicenter, retrospective study of 
1124 Japanese patients followed for a median 
period of 66 months [46] reported an incidence of 
HCC of 3.5% among 373 SVR patients. About 
the temporal relationship between SVR achieve-
ment and diagnosis of HCC, some groups 
reported that HCCs are usually detected within 
5 years after the end of therapy – thus speculat-
ing that HCC was already present but too small 
to be detected before the start of therapy [43,44] 
– while Kobayashi et al. emphasized how in 8 of 
their 13 SVR patients who developed HCC, the 
tumor was detected more than 5 years (up to 
12 years) after the end of IFN therapy, and the 
temporal interval to the detection of HCC was 
not significantly different between SVR and 
non-SVR patients [46]. Common to all these 
reports, older age, male sex and advanced his-
tologic stage were identified as the main inde-
pendent risk factors for the future development 
of HCC among patients with an SVR.
Although the reasons why some SVR patients 
will develop HCC are still unclear, it is likely that 
a certain degree of fibrosis regression/cirrhosis 
reversal might be a key factor. This issue was 
suggested by Mallet and colleagues in their ret-
rospective study of 96 HCV cirrhotic patients 
who had at least one liver biopsy after antiviral 
treatment completion [47]. After a median fol-
low-up of 118 months, cirrhosis regression was 
observed in 19% of patients (all but one achieved 
SVR) and was associated with significant reduc-
tion of liver decompensation and HCC develop-
ment, whereas patients without signs of cirrhosis 
regression developed liver complications (0% 
in patients with cirrhosis regression, 22.1% in 
patients without, p = 0.036), including HCC; 
furthermore, all three SVR patients who devel-
oped HCC despite viral eradication had per-
sistent cirrhosis on the follow-up biopsy [47]. 
However, independent of histological features, 
the identification of clinical risk factors associ-
ated with a high risk of HCC development in 
sustained responders stands as the most relevant 
issue in order to detect those patients who need 
to be closely monitored after the end of treat-
ment. Some of these risk factors have been easily 
identified, namely patient age – possibly reflect-
ing a long duration of infection or an increased 
prevalence of cirrhosis and other risk factors 
for HCC in aged population – and advanced 
fibrosis/cirrhosis [14,24]. Interestingly, some of 
the features able to predict HCC development 
in viremic patients – such as advanced age, 
advanced fibrosis, degree of portal hypertension 
and elevated α-fetoprotein levels – have been 
identified as independent predictors of HCC 
also in SVR patients [48]. In addition, recent data 
have emphasized the potential role of metabolic 
and exogenous players, such as diabetes, obesity, 
insulin resistance and alcohol abuse, in promot-
ing the development of HCC in SVR patients, 
acting as autonomous, nonviral carcinogenic 
factors [49,51]. In this line, a recent Taiwanese 
study [50], performed among 642 patients who 
achieved an SVR after pegylated-IFN plus 
Ribavirin therapy, showed that the strongest 
predictive factor of HCC occurrence in this 
cohort was liver cirrhosis, followed by age and 
gamma-glutamyl transpeptidase (GGT) levels 
– a well-known marker of metabolic syndrome 
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and its features, of liver fibrosis and its progres-
sion and of malignancies [52]. Although the inci-
dence of HCC did not differ between cirrhotic 
patients with high and low baseline GGT levels, 
the incidence of HCC was significantly higher in 
noncirrhotic patients with high GGT levels com-
pared with those with low GGT levels. Thus, 
the authors suggested that GGT levels may be 
a potential novel marker of high risk of HCC 
development in noncirrhotic SVR patients. 
Another interesting study on this topic ana-
lyzed 871 SVR patients [48]: authors computed a 
numerical score based on age, sex, platelet count, 
serum α-fetoprotein levels, Metavir stage and 
diabetes – the most intriguing factor. This score 
allowed to estimate the 5-year HCC risk after 
SVR achievement so to stratify all patients into 
low-, medium- and high-risk patients [48].
In conclusion, despite the majority of SVR 
patients benefit a substantial reduction of HCC 
risk, particularly those young, with mild fibrosis 
and/or with fibrosis regression/cirrhosis rever-
sal, a residual risk exists, particularly in older 
patients with advanced fibrosis and comorbidities 
linked to diabetes, overweight and alcohol abuse. 
Predictors of high risk of HCC development in 
responder patients should be promptly identi-
fied in order to provide cost-effective screening 
programs of HCC also in SVR patients.
HCv-induced carcinogenesis & residual 
risk of HCC after SvR achievement: 
pathophysiological insight
Unlike in an HBV scenario, a successful antiviral 
treatment against HCV infection results in viral 
clearance. As discussed above, this translates in 
an approximately threefold reduction in the risk 
of HCC in cirrhotic patients, and in a much 
greater benefit, in other words, almost the elimi-
nation of any risk, in noncirrhotic ones [39,42]. 
Therefore, it is obvious that HCV infection is 
a risk factor for liver cancer, even if it is still 
unclear whether HCV is directly carcinogenic 
or if simply triggers an inflammatory/profibrotic 
response that favors cancer development [53]. The 
most accepted hypothesis is that HCV is able 
to elicit both direct and indirect effects on liver 
cells that may promote their neoplastic trans-
formation. Regarding direct effects, it is estab-
lished how a constitutive expression of a viral 
oncogene or the integration of viral sequences 
into the genome of host cells are not involved in 
Table 2. Summary of the main studies focused specifically on the residual risk of hepatocellular carcinoma among HCv patients 
who achieved a sustained virological response.
Study (year) Country Main findings Ref.
Toyoda et al. (2000)  Japan HCC was detected in 8 out of 392 SVR patients: in seven patients HCC developed within 5 years 
after completion of IFN therapy, and after 7–8 years in one patient
[43]
Makiyama et al. (2004) Japan Among 1197 sustained responders, 27 patients developed HCC (2.3%). Compared with sustained 
responders who did not develop HCC, patients who developed the disease more often were 
male, older and had advanced-stage histologic disease before IFN therapy
[44]
Ekonimura et al. (2003) Japan Among 142 SVR patients, six (4.2%) developed HCC after an average interval between IFN 
therapy and diagnosis of HCC of 59.2 months. Five of the six cases were single HCC, and the 
remainder were multifocal
[45]
Kobayashi et al. (2007) Japan HCC developed in 3.5% of SVR patients. As compared with SVR patients without HCC, SVR 
patients with HCC were predominantly male, older and at a more advanced histologic stage of 
disease; three of the 13 SVR HCC patients had mild fibrosis
[46]
Mallet et al. (2008) France Among 96 HCV cirrhotic patients with at least one liver biopsy after antiviral treatment 
completion, cirrhosis regression was associated with significant reduction of liver 
decompensation and HCC development, whereas patients without signs of cirrhosis regression 
developed liver complications; all three SVR patients who developed HCC despite viral 
eradication had persistent cirrhosis on the follow-up biopsy
[47]
Chang et al. (2012) Taiwan Older age, high α-fetoprotein levels, low platelet count and advanced fibrotic stage were 
independent risk factors for HCC development among 871 SVR patients and were used to 
compute a risk score
[48]
Arase et al. (2013) Japan Type 2 diabetes causes an approximately 1.7-fold enhancement in the development of HCC and 
malignancies other than HCC in HCV-positive patients treated with IFN
[49]
Huang et al. (2014) Taiwan A 5.1% of SVR patients developed HCC over 2324.8 person-years of follow-up. Risk factors for 
HCC occurrence were cirrhosis, age and γGT levels; the incidence of HCC was significantly higher 
in noncirrhotic patients with high γGT levels compared with those with low γGT levels
[50]
HCC: Hepatocellular carcinoma; SVR: Sustained virological response.
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HCV-related HCCs. Instead, in vitro models led 
to hypothesize that HCV is able to interfere with 
several cellular functions in order to promote its 
survival in the liver, resulting in an enhancement 
of all processes involved in viral replication, and 
in the dismantlement of the immune responses 
of the host. Interestingly, some of these interac-
tions involve cellular proteins with critical roles 
in controlling cell proliferation checkpoints and 
thus with tumor-suppressor properties [54]. The 
most studied interaction involves the binding 
between the viral nonstructural protein NS5B 
and the retinoblastoma (Rb) protein, which 
results in the fast degradation of cellular Rb. Rb 
is a relevant protein for host cells, since it controls 
the G1 to S-phase transition and other crucial 
checkpoints of cell cycle. HCV takes advantage 
of such mechanism to overcome possible blocks 
to cell-cycle progression [55,56]; unfortunately, Rb 
also regulates several cellular responses to DNA 
damages, all of them being critical controls in 
the prevention of neoplastic transformation [57], 
so that its impaired function may promote 
genomic instability [58]. Furthermore, typical 
of HCV-related HCCs is the expression of the 
liver-specific microRNA (miR)-122, a host cell 
factor that is necessary for HCV replication and 
has also relevant tumor-suppressor properties in 
the liver [59]. In addition, the artificial overexpres-
sion of HCV proteins – including core, NS3 and 
NS5A – causes cellular proliferation and tumor 
formation in mice, thus suggesting a potential 
direct contribution in activating oncogenic 
molecular pathways [60–63]. Therefore, the repli-
cative cycle of HCV seems to be directly linked 
to procarcinogenic cellular phenomena [53]. 
Regarding indirect mechanisms, it is well known 
how viral replication itself stands as a continu-
ous stimulus to the induction of pro-inflamma-
tory and pro-apoptotic signals [64]. Apoptosis is 
compensated by a marked cellular proliferation 
occurring in a background of oxidative stress and 
inflammation due to the release of several media-
tors by the infected liver cells. As a consequence, 
DNA damage may occur also in uninfected liver 
cells [64]. All in all, HCV proteins – both directly 
and indirectly – promote immune evasion, cel-
lular deregulation and inf lammation, thus 
producing fibrogenesis, oxidative stress, DNA 
damage and genetic instability: these phenom-
ena altogether are capable to create and expand 
tumor-initiating/cancer stem cells [63].
On this basis, it may be easily understood 
why a successful HCV eradication – erasing 
both direct and indirect HCV-induced carcino-
genic effects – results in a significant reduction 
of HCC risk. However, as previously discussed, 
this risk is not completely eliminated (Figure 1). 
Of course, the occurrence of HCC in SVR 
patients may reflect the interval of time nec-
essary for pre-existing small HCCs to become 
clinically evident [37]; however, this hypothesis 
could explain only a fraction of HCC occur-
ring after SVR, in other words, those developed 
early after completion of antiviral therapy. For 
all others, it should be noted that the persistence 
of residual procarcinogenic effects of cirrhosis, 
whose structural and vascular alterations consti-
tute an environmental background able to pro-
duce hepatocyte proliferation and cell cycle dys-
regulation. In other words, established cirrhosis 
serves as fertile soil for all processes of initiation 
and promotion of neoplastic clones by promot-
ing genetic aberration pathways and cellular 
transformation [65], so that cirrhosis-driven car-
cinogenesis is regarded as the main mechanism 
involved in the development of HCV-related 
HCCs [66]. This statement is coherent with 
the above-discussed evidences revealing the 
greatest reduction of HCC risk in patients who 
experienced a histological reversion of cirrho-
sis [47]. In addition, animal models have shown 
that chronic immune-mediated liver damage is 
overall sufficient for the development of HCC, 
and that viral mechanisms of carcinogenesis are 
not required [67]. So, persistence of liver necro-
inflammation likely serves as a relevant cause of 
the increased risk of HCC associated with the 
presence, after SVR achievement, of well-known 
nonviral carcinogenic risk factors such as obe-
sity, insulin resistance, steatosis, Type 2 diabetes 
and alcohol [68]. Furthermore, molecular path-
ways of fibrogenesis – the result of the wound 
healing response induced by necroinflammation 
– are tightly associated with the development of 
DNA damage in the hepatocytes. The interplay 
between mechanisms of inflammation, fibrosis 
and carcinogenesis is complex and still elusive. 
A central role could be played by NF-κB, a 
master regulator of inflammation and all linked 
processes acting as key factor on cellular cycle 
and survival of parenchymal and nonparen-
chymal liver cells [69], although other several 
mediators – including JNK, TGF-β, PDGF-β, 
COX-2 and many more – and related path-
ways could be potentially involved [65]. Even 
if eradication of HCV strongly reduces these 
pathological mechanisms, the first steps in liver 
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Figure 1. A successful HCv eradication erases both direct and indirect HCv-induced carcinogenic 
effects, and can induce a certain degree of histological reversion of cirrhosis in a proportion 
of patients. However, the persistence of residual procarcinogenic effects of cirrhosis and the 
presence of nonviral carcinogenic risk factor acting as a continuous stimulus to the induction of 
inflammation-fibrosis-carcinogenesis pathways do not eliminate completely the risk of HCC despite 
the achievement of an SVR. 
HCC: Hepatocellular carcinoma; SVR: Sustained virological response.
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carcinogenesis probably occur at early stages of 
CHC, so that a certain risk of HCC persists 
even if fibrosis has decreased. However, it is 
important to note that most of these observa-
tions have been derived from cell cultures or 
animal models overexpressing single proteins. 
Consequently, the real relevance of these find-
ings for human hepatic carcinogenesis needs to 
be confirmed [63].
Conclusion
Current data are enough to state that a sub-
stantial reduction of the risk for future HCC 
development occurs following eradication 
of HCV infection, as a result of the suppres-
sion of both direct and indirect carcinogenic 
effects induced by HCV. However, a residual 
risk of HCC exists in SVR patients. Indeed, 
some HCCs could be already present, but too 
small to be detected, before the start of antiviral 
therapy, so we have to consider that a certain 
time interval can be required for small HCCs 
to become clinically evident. In addition, phy-
sicians should keep in mind that the residual 
risk of HCC in SVR patients correlates with 
patient age, possibly reflecting the increased 
prevalence of cirrhosis and other risk factors 
for HCC in aged population, and with the 
amount of histological injury, as reflection of 
the typical procarcinogenic effects of cirrhosis. 
Furthermore, evidence is growing that failure 
of HCC prevention in SVR patients may be 
also consequent to the persistence of necroin-
flammatory/fibrogenetic mechanisms driven by 
nonviral carcinogenic factors like diabetes, obe-
sity and alcohol abuse. On these assumptions, 
it seems reasonable that patients with hepati-
tis C and advanced fibrosis/cirrhosis should 
continue to undergo surveillance despite the 
achievement of an SVR [70], and that all proper 
lifestyle modifications be implemented in order 
to avoid all preventable carcinogenic risk factors 
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such as alcohol drinking, insulin resistance and 
steatosis.
Future perspective
The next availability of safe IFN-free regimens 
will certainly lead to an expansion of the current 
criteria of anti-HCV therapy that have excluded 
patients unfit to IFN/ribavirin regimens due to 
decompensated cirrhosis and/or severe comor-
bidities, who are closest to HCC occurrence. 
This revolution in the HCV scenario will over-
come one of the past methodological issues for the 
evaluation of the burden of SVR on the reduction 
of HCC risk, as ineligibility of patients with severe 
comorbidities and those with advanced or decom-
pensated CHC might have caused two compet-
ing risk factors of shortened survival – HCC and 
all-cause mortality – to appear reduced in the 
cohorts of HCV patients who achieved an SVR. 
Similar to what has been observed with the advent 
of nucleos(t)ide analog therapy in HBV, patients 
with decompensated HCV – cirrhosis may show 
a clinical improvement, and a sharp reduction of 
deaths for liver decompensation can be expected. 
executive summAry
HCv-related hepatocellular carcinoma
 ●  Hepatocellular carcinoma (HCC) is the second cause of cancer-related death worldwide.
 ●  HCV infection stands today as the leading risk factor for HCC in many industrialized countries.
 ●  Antiviral treatment is regarded as the main prophylaxis strategy for the prevention of HCV-related HCC.
The role of antiviral treatment for the prevention of HCv-related HCC
 ●  The evidence that patients with chronic hepatits C are effectively protected against HCC risk by IFN-based regimens is 
rather controversial due to several methodological concerns of the literature.
 ●  A real clinical benefit is gained only in patients achieving a sustained virological response (SVR) rather than in 
nonresponders.
 ●  SVR confers an almost 80% reduction of the HCC risk across all the clinical stages of chronic hepatitis C compared with 
non-SVR.
 ●  HCV-related HCC is more likely to be prevented in young patients with mild fibrosis achieving an SVR, rather than in 
elderly patients with cirrhosis.
The residual risk of HCC among SvR patients
 ●  The risk for HCC is not completely eliminated following HCV eradication.
 ●  Older age and advanced histologic stage have been identified as the main independent risk factors for the future 
development of HCC among patients with SVR.
 ●  Lack of a certain degree of fibrosis regression/cirrhosis reversal after SVR might be a risk factor for HCC occurrence.
 ●  Recent evidences have emphasized the potential role of metabolic factors such as diabetes, obesity, insulin resistance 
and alcohol abuse, in promoting the development of HCC in SVR patients.
 ●  Predictors of high risk of HCC development in SVR patients should be promptly identified in order to provide cost-
effective screening programs of HCC also in SVR patients.
Pathophysiological insight
 ●  HCV proteins – both directly and indirectly – promote immune evasion, cellular deregulation and inflammation, 
thus producing fibrogenesis, oxidative stress, DNA damage and genetic instability: these phenomena altogether are 
capable to create and expand tumor-initiating/cancer stem cells.
 ●  The persistence of residual procarcinogenic effects of cirrhosis and the potential presence of mechanisms of liver 
injury due to metabolic factors can promote the development of HCC in SVR patients acting as autonomous, nonviral 
carcinogenic factors.
 ●  Several mediators – including JNK, TGF-β, PDGF-β, COX-2 and NF-κB – are involved and intimately related in processes 
of fibrogenesis, necroinflammation and carcinogenesis.
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The next years will clarify whether the risk of 
HCC occurrence will decline drastically also in 
patients with decompensated cirrhosis after SVR 
achievement, or if there will be a sort of point of 
no return beyond which the risk of HCC will be 
poorly affected by the SVR. Anyways, further 
efforts should be done in order to identify the 
patients carrying real risk factors associated with 
a high risk of HCC development even after HCV 
eradication, who could ideally benefit from other 
chemopreventive therapies targeting the molecu-
lar basis of liver oncogenesis. Finally, the broad 
applicability of IFN-free regimens will clarify if 
HCV eradication could be a tool also for tertiary 
chemoprevention of HCC – in other words, if 
it will produce a delay or prevention of second 
primary tumors in patients who have undergone 
a successful tumor eradication with resection or 
ablation.
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